Do analysts recommend LIXT or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, LIXT or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is LIXT or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Invizyne Technologies N/A N/A N/A

Do analysts prefer IZTC or CUE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, IZTC or CUE?

Invizyne Technologies has higher earnings, but lower revenue than Cue Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Cue Biopharma $27.47M 5.23 -$26.60M -$5.58 N/A

Do analysts prefer GUTS or IZTC?

Fractyl Health presently has a consensus target price of $5.12, indicating a potential upside of 652.94%. Given Fractyl Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Fractyl Health is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fractyl Health 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GUTS or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Fractyl Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health $90K 1,202.69 -$140.95M -$0.88 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is GUTS or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -960.07% -79.25% Invizyne Technologies N/A N/A N/A

Do analysts prefer DTSQ or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, DTSQ or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is DTSQ or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Invizyne Technologies N/A N/A N/A

Do analysts prefer IZTC or COYA?

Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 220.11%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher valuation and earnings, IZTC or COYA?

Invizyne Technologies has higher earnings, but lower revenue than Coya Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Coya Therapeutics $7.95M 14.14 -$21.23M -$1.07 N/A

Invizyne Technologies (IZTC) Competitors

$6.00 +0.24 (+4.17%)

As of 08/13/2026

Compare

IZTC vs. LIXT, CUE, GUTS, DTSQ, and COYA

Should you buy Invizyne Technologies stock or one of its competitors? Invizyne Technologies's main competitors and comparable companies include Lixte Biotechnology (LIXT), Cue Biopharma (CUE), Fractyl Health (GUTS), DT Cloud Star Acquisition (DTSQ), and Coya Therapeutics (COYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invizyne Technologies compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Lixte Biotechnology had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Invizyne Technologies. Lixte Biotechnology's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Invizyne Technologies	Neutral

Invizyne Technologies' return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Invizyne Technologies	N/A	N/A	N/A

5.1% of Lixte Biotechnology shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Lixte Biotechnology beats Invizyne Technologies on 4 of the 6 factors compared between the two stocks.

How does Invizyne Technologies compare to Cue Biopharma?

Invizyne Technologies (NASDAQ:IZTC) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Invizyne Technologies has higher earnings, but lower revenue than Cue Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Cue Biopharma	$27.47M	5.23	-$26.60M	-$5.58	N/A

In the previous week, Cue Biopharma had 5 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for Cue Biopharma and 0 mentions for Invizyne Technologies. Cue Biopharma's average media sentiment score of 0.62 beat Invizyne Technologies' score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Cue Biopharma	Positive

Invizyne Technologies has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Invizyne Technologies' return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Cue Biopharma	-59.65%	-98.30%	-53.69%

35.0% of Cue Biopharma shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cue Biopharma beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

How does Invizyne Technologies compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Invizyne Technologies has lower revenue, but higher earnings than Fractyl Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,202.69	-$140.95M	-$0.88	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Fractyl Health presently has a consensus target price of $5.12, indicating a potential upside of 652.94%. Given Fractyl Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Fractyl Health is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Fractyl Health had 19 more articles in the media than Invizyne Technologies. MarketBeat recorded 19 mentions for Fractyl Health and 0 mentions for Invizyne Technologies. Fractyl Health's average media sentiment score of 0.88 beat Invizyne Technologies' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Overall Sentiment
Fractyl Health	Positive
Invizyne Technologies	Neutral

Invizyne Technologies' return on equity of 0.00% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-960.07%	-79.25%
Invizyne Technologies	N/A	N/A	N/A

Summary

Fractyl Health beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks.

How does Invizyne Technologies compare to DT Cloud Star Acquisition?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, DT Cloud Star Acquisition had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for DT Cloud Star Acquisition and 0 mentions for Invizyne Technologies. DT Cloud Star Acquisition's average media sentiment score of 0.96 beat Invizyne Technologies' score of 0.00 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
DT Cloud Star Acquisition	Positive
Invizyne Technologies	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

DT Cloud Star Acquisition beats Invizyne Technologies on 3 of the 3 factors compared between the two stocks.

How does Invizyne Technologies compare to Coya Therapeutics?

Invizyne Technologies (NASDAQ:IZTC) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

39.8% of Coya Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 220.11%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Invizyne Technologies has higher earnings, but lower revenue than Coya Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Coya Therapeutics	$7.95M	14.14	-$21.23M	-$1.07	N/A

In the previous week, Coya Therapeutics had 12 more articles in the media than Invizyne Technologies. MarketBeat recorded 12 mentions for Coya Therapeutics and 0 mentions for Invizyne Technologies. Coya Therapeutics' average media sentiment score of 0.38 beat Invizyne Technologies' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Coya Therapeutics	Neutral

Invizyne Technologies has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Invizyne Technologies' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Coya Therapeutics	-270.22%	-53.20%	-46.92%

Summary

Coya Therapeutics beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IZTC vs. The Competition

Export

Metric	Invizyne Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$37.51M	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	N/A	10.68	269.86	25.30
Price / Sales	N/A	1,308.25	601.81	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	N/A	17.49	13.08	6.33
Net Income	N/A	-$13.32M	$3.45B	$347.70M
7 Day Performance	16.16%	1.74%	1.12%	1.07%
1 Month Performance	-5.81%	1.60%	1.79%	1.03%
1 Year Performance	-39.94%	56.43%	67.69%	20.77%

Invizyne Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IZTC Invizyne Technologies	N/A	$6.00 +4.2%	N/A	-42.6%	$37.51M	N/A	N/A	29	Gap Up
LIXT Lixte Biotechnology	0.0558 of 5 stars	$7.51 +4.2%	N/A	+85.0%	$112.80M	N/A	N/A	4	News Coverage Gap Up
CUE Cue Biopharma	0.2463 of 5 stars	$26.84 -11.7%	N/A	-95.7%	$112.74M	$27.47M	N/A	60	Earnings Report Gap Up High Trading Volume
GUTS Fractyl Health	3.9499 of 5 stars	$0.69 -0.7%	$5.12 +647.4%	-34.5%	$108.67M	$90K	N/A	102	News Coverage Earnings Report Analyst Revision Gap Up
DTSQ DT Cloud Star Acquisition	1.8583 of 5 stars	$11.34 +0.1%	N/A	+8.5%	$100.76M	N/A	N/A	N/A	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invizyne Technologies (IZTC) Competitors

IZTC vs. LIXT, CUE, GUTS, DTSQ, and COYA

How does Invizyne Technologies compare to Lixte Biotechnology?

Summary

How does Invizyne Technologies compare to Cue Biopharma?

Summary

How does Invizyne Technologies compare to Fractyl Health?

Summary

How does Invizyne Technologies compare to DT Cloud Star Acquisition?

Summary

How does Invizyne Technologies compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invizyne Technologies (IZTC) Competitors

IZTC vs. LIXT, CUE, GUTS, DTSQ, and COYA

How does Invizyne Technologies compare to Lixte Biotechnology?

Do analysts recommend LIXT or IZTC?

Which has preferable earnings & valuation, LIXT or IZTC?

Does the media prefer LIXT or IZTC?

Is LIXT or IZTC more profitable?

Do institutionals and insiders hold more shares of LIXT or IZTC?

Summary

How does Invizyne Technologies compare to Cue Biopharma?

Which has better valuation and earnings, IZTC or CUE?

Does the media favor IZTC or CUE?

Is IZTC or CUE more profitable?

Do institutionals & insiders have more ownership in IZTC or CUE?

Do analysts prefer IZTC or CUE?

Summary

How does Invizyne Technologies compare to Fractyl Health?

Which has better valuation & earnings, GUTS or IZTC?

Do analysts prefer GUTS or IZTC?

Does the media favor GUTS or IZTC?

Is GUTS or IZTC more profitable?

Summary

How does Invizyne Technologies compare to DT Cloud Star Acquisition?

Does the media refer more to DTSQ or IZTC?

Which has preferable valuation & earnings, DTSQ or IZTC?

Is DTSQ or IZTC more profitable?

Do analysts prefer DTSQ or IZTC?

Summary

How does Invizyne Technologies compare to Coya Therapeutics?

Do insiders and institutionals hold more shares of IZTC or COYA?

Do analysts prefer IZTC or COYA?

Which has higher valuation and earnings, IZTC or COYA?

Does the media prefer IZTC or COYA?

Is IZTC or COYA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools